Alnylam Pharmaceuticals (ALNY) Announces Manufacturing Agreement With Dowpharma (DOW) For RNAi Therapeutics 
10/19/2005 5:13:09 PM

CAMBRIDGE, Mass. & MIDLAND, Mich.--(BUSINESS WIRE)--March 29, 2005--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Dowpharma(SM), a business unit of The Dow Chemical Company (NYSE: DOW), announced today an agreement for the manufacture and supply of candidate RNAi therapeutics for Alnylam's lead development programs in age-related macular degeneration (AMD) and respiratory syncytial virus (RSV) infection. Dowpharma will manufacture short interfering RNAs (siRNAs), the molecules that induce RNAi, for use in clinical trials. "This agreement is an important step in our transition to a clinical-stage company as we rapidly advance multiple RNAi therapeutic candidates into human trials," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam Pharmaceuticals. "Dowpharma is a high-quality partner who will provide Alnylam access to large-scale synthesis and purification of siRNAs necessary for clinical development."